- Home
- REFI vs JSPR Comparison
REFI vs JSPR Comparison
Compare REFI & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | JSPR |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 48.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | REFI | JSPR |
|---|---|---|
| Price | $13.11 | $1.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $20.00 | ★ $21.44 |
| AVG Volume (30 Days) | 119.8K | ★ 4.0M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 15.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $54,287,847.00 | N/A |
| Revenue This Year | $13.78 | N/A |
| Revenue Next Year | $4.07 | N/A |
| P/E Ratio | $7.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.85 | $1.39 |
| 52 Week High | $16.29 | $22.99 |
Technical Indicators
Market Signals| Indicator | REFI | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 55.08 | 47.03 |
| Support Level | $12.76 | $1.61 |
| Resistance Level | $13.25 | $1.96 |
| Average True Range (ATR) | 0.28 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 56.18 | 46.25 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.